title: Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris.
abstract: BACKGROUND
  Blue light irradiation reduces the proliferation of keratinocytes and modulates T-cell immune response in vitro and has been shown to reduce the severity of psoriasis vulgaris (Pv) in two clinical trials.
  
  
  OBJECTIVE
  Evaluation of safety and efficacy of long-term UV-free blue light treatment at home for mild Pv.
  
  
  METHODS
  Forty-seven patients with mild Pv were randomized for receiving high-intensity blue light treatment (HI: 453 nm LED, 200 mW/cm(2), n = 24) and low-intensity treatment (LI: 453 nm LED, 100 mW/cm(2), n = 23) of one Pv plaque for 12 weeks. A contralateral control plaque remained untreated.
  
  
  RESULTS
  Patient compliance and satisfaction were high. The primary endpoint, change from baseline (CfB) of the Local Psoriasis Severity Index, revealed a significant improvement of the target compared to the control plaques (ΔCfB for the HI group: -0.92 ± 1.10, p = 0.0005; for the LI group: -0.74 ± 1.18, p = 0.0064).
  
  
  CONCLUSIONS
  UV-free blue light home treatment is safe and improves Pv plaques.
authors.affiliation: Department of Dermatology and Allergology, University Hospital, RWTH Aachen University, Aachen, Germany.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Pfaff
authors.forename: Jörg
authors.initials: J
authors.lastname: Liebmann
authors.forename: Matthias
authors.initials: M
authors.lastname: Born
authors.forename: Hans F
authors.initials: HF
authors.lastname: Merk
authors.forename: Verena
authors.initials: V
authors.lastname: von Felbert
mesh_terms: D000328:Adult; D000368:Aged; D016500:Color Therapy / Q000009:adverse effects / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017060:Patient Satisfaction; D011446:Prospective Studies; D011565:Psoriasis / Q000628:therapy*; D012720:Severity of Illness Index; D013997:Time Factors; D055815:Young Adult